Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangie Kush is a named **cannabis chemovar/strain** developed by Amsterdam Genetics by crossing Tangie with Kosher Kush. It is generally described as an indica-dominant hybrid with high tetrahydrocannabinol exposure and relatively low cannabidiol content, with beta-caryophyllene and limonene often cited among the dominant terpenes. Its pharmacology is not that of a single purified pharmaceutical active ingredient; rather, its effects are driven by inhaled or ingested cannabis constituents, principally delta-9-tetrahydrocannabinol acting as a cannabinoid receptor agonist, together with potential entourage contributions from minor cannabinoids and terpenes. Tangie Kush is marketed and discussed primarily as a recreational cannabis strain, though it is also informally associated with symptomatic use for pain, stress, low mood, insomnia, and appetite stimulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tangie Kush.